

Appln No.: 09/913,325
Amendment Dated: December 6, 2007
Response to Official Action dated June 14, 2007

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-5. (canceled)

6. (currently amended) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide that is complementary to a region of the TRPM-2 mRNA that is complementary to SEQ ID NO.: 4.

7-8. (canceled)

9. (previously presented) The method of claim 6, wherein the antisense oligonucleotide consists of the sequence given by SEQ ID No. 4.

10. (canceled)

11. (currently amended) The method of claim ~~37~~ -6, wherein the antisense oligonucleotide consists of the sequence given by SEQ ID No. 12.

12 -28. (canceled)

Appln No.: 09/913,325
Amendment Dated: December 6, 2007
Response to Official Action dated June 14, 2007

29. (previously presented) The method of claim 9, further comprising the step of administering to the individual a chemotherapy agent.

30. (previously presented) The method of claim 9, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

31-32. (canceled)

33. (previously presented) The method of claim 11, further comprising the step of administering to the individual a chemotherapy agent.

34. (previously presented) The method of claim 11, further comprising the step of administering to the individual a second antisense oligodeoxynucleotide which inhibits expression of an anti-apoptotic protein other than TRPM-2.

35-36 (canceled)

37. (currently amended) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of initiating androgen-withdrawal to induce apoptotic cell death of prostatic tumor cells in the individual, and administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, thereby delaying the progression of prostatic tumor cells to an androgen-independent state in an individual, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide that ~~The method of claim 6, wherein the antisense oligonucleotide is complementary to a region of the TRPM-2 mRNA that is complementary to SEQ ID NO: 12.~~

Appln No.: 09/913,325
Amendment Dated: December 6, 2007
Response to Official Action dated June 14, 2007

38. (previously presented) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, and administering to the individual a chemotherapy agent, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide comprising the sequence given by SEQ ID No. 4.

39. (previously presented) The method of claim 38, wherein the chemotherapy agent is a taxane or mitoxanthrone.

40-42 (canceled)

43. (currently amended) A method for treating prostate cancer in an individual suffering from prostate cancer, comprising the steps of administering to the individual a composition effective to inhibit expression of TRPM-2 by the tumor cells, and administering to the individual a chemotherapy agent, wherein the composition effective to inhibit expression of TRPM-2 is an antisense oligonucleotide comprising ~~The method of claim 38, wherein the antisense oligonucleotide comprises~~ the sequence given by SEQ ID No. 12.

44. (new) The method of claim 43, wherein the chemotherapy agent is a taxane or mitoxanthrone.